transmembrane protein 167AGenealiases: TMEM167 · kish
Q-omics provides the consensus-scored TMEM167A profile across patient tissues and cancer cell-line models. TMEM167A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM167A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TMEM167A protein abundance shows 21,295 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where TMEM167A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM167A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM167A survival associations across molecular data types. TMEM167A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM167A RNA expression–survival associations across cancer types. High TMEM167A expression shows unfavorable associations in KIRP, STAD, UVM, KICH, OV and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM167A RNA expression.
This table summarizes TMEM167A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM167A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM167A shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, KIRC and STAD. The HNSC box plot shows higher TMEM167A RNA expression in tumor versus normal tissue (log2 FC = +1.136, t-test p < 0.001).
This table shows molecular features associated with TMEM167A in patient tissues and cancer cell lines. In patient samples, TMEM167A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM167A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
